Omics Lab Services

Global Omics Lab Services Market to Reach US$172.7 Billion by 2030

The global market for Omics Lab Services estimated at US$87.0 Billion in the year 2024, is expected to reach US$172.7 Billion by 2030, growing at a CAGR of 12.1% over the analysis period 2024-2030. Omics Lab Hardware Equipment, one of the segments analyzed in the report, is expected to record a 10.2% CAGR and reach US$92.3 Billion by the end of the analysis period. Growth in the Omics Lab Testing / Lab Services segment is estimated at 14.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$23.7 Billion While China is Forecast to Grow at 16.0% CAGR

The Omics Lab Services market in the U.S. is estimated at US$23.7 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$35.6 Billion by the year 2030 trailing a CAGR of 16.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.0% and 10.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.5% CAGR.

Global Omics Lab Services Market – Key Trends & Drivers Summarized

Why Are Omics Lab Services at the Core of Precision Medicine and Biomedical Innovation?

Omics lab services, which encompass genomics, transcriptomics, proteomics, metabolomics, and epigenomics, are revolutionizing life sciences and healthcare by enabling high-resolution insights into biological systems at the molecular level. These services allow researchers and clinicians to decode complex biological data and uncover gene-protein-metabolite interactions that underpin health, disease, and therapeutic response. As the foundation of precision medicine, omics lab services are increasingly used in oncology, rare disease diagnostics, pharmacogenomics, microbiome studies, and biomarker discovery. The ability to perform whole genome sequencing, RNA profiling, protein expression analysis, and metabolic pathway mapping from clinical or experimental samples is empowering scientists to tailor therapies, improve diagnostic accuracy, and predict treatment outcomes. Advanced next-generation sequencing (NGS), high-throughput mass spectrometry, and bioinformatics platforms have made omics studies faster, more affordable, and more scalable than ever. This is accelerating their integration into drug discovery pipelines, clinical trials, population health studies, and companion diagnostic development. As personalized medicine moves from concept to clinical reality, demand for high-quality, full-spectrum omics lab services is surging across academic, commercial, and healthcare sectors worldwide.

How Are Technology Advancements and AI Shaping the Future of Omics Services?

The exponential growth in data generation through omics platforms has made technology and computational power key enablers in the evolution of lab services. Advanced sequencing platforms, single-cell analysis technologies, and high-resolution mass spectrometry tools are enhancing the depth, speed, and precision of molecular profiling. Meanwhile, artificial intelligence (AI), machine learning (ML), and data visualization tools are revolutionizing how complex omics data sets are analyzed, interpreted, and applied to real-world problems. AI-driven analytics are uncovering hidden patterns in multi-omics data, enabling breakthroughs in disease mechanism elucidation, target identification, and biomarker validation. Additionally, cloud computing and decentralized data architectures are supporting large-scale collaborative research and real-time data sharing among institutions across the globe. These innovations are also enabling integration of multiple omics layers (multi-omics), providing a more comprehensive systems biology view that facilitates a deeper understanding of disease phenotypes and molecular mechanisms. Moreover, automation in sample preparation, sequencing workflows, and data pipelines is increasing lab efficiency and reproducibility. These technological strides are not only driving demand for omics lab services but are also making them accessible to a broader range of customers, including biotech startups, academic researchers, pharmaceutical companies, and clinical labs.

Is the Rise of Personalized Healthcare Accelerating Adoption of Omics-Based Services?

The global healthcare paradigm shift toward personalized and preventive medicine is a major catalyst for the growth of omics lab services. Healthcare systems and payers are increasingly focused on early detection, risk stratification, and patient-specific treatment strategies—all of which require deep molecular profiling enabled by omics technologies. In oncology, for instance, tumor sequencing and transcriptome analysis are routinely used to guide targeted therapies and immunotherapy selection. In reproductive medicine, preimplantation genetic testing and carrier screening based on genomics are becoming standard practice. Population genomics initiatives in countries like the U.S., China, the U.K., and the UAE are accelerating the use of omics data in national health planning, paving the way for disease prevention strategies tailored to genetic risk. Additionally, growing consumer interest in wellness genomics, ancestry testing, nutrigenomics, and microbiome health is expanding the application of omics services beyond clinical settings. Direct-to-consumer genetic testing firms are increasingly partnering with specialized omics labs to deliver personalized health reports and actionable insights. Insurance providers and pharmaceutical companies are also investing in omics-driven approaches to reduce healthcare costs, improve patient outcomes, and increase drug efficacy. As precision health becomes a global priority, omics lab services are transitioning from research-centric tools to essential components of mainstream healthcare and consumer wellness.

What’s Powering the Rapid Growth of the Global Omics Lab Services Market?

The growth in the omics lab services market is driven by several factors related to the expansion of precision medicine, rapid technological advancement, rising healthcare expenditure, and cross-sector collaborations. A key driver is the increasing demand from pharmaceutical and biotech companies for omics-based insights in drug discovery, companion diagnostics, and clinical trial optimization. The growing complexity of diseases like cancer, neurological disorders, and metabolic syndromes is compelling researchers to adopt multi-omics strategies for deeper biological understanding and targeted intervention. Academic and government-funded research initiatives are also fueling demand, with large-scale population genomics programs, cancer genome atlases, and microbiome projects requiring specialized omics infrastructure and services. Additionally, the shift toward personalized medicine in clinical practice is creating sustained demand for diagnostic and prognostic tools powered by omics data. On the technological side, cost reductions in sequencing, improvements in sample processing automation, and cloud-based bioinformatics platforms are making omics services more scalable and accessible. Increasing public and private investments in omics research, particularly in genomics and proteomics, are further accelerating market expansion. Collaborations between CROs, hospitals, diagnostic labs, and AI firms are enhancing the value chain, enabling end-to-end omics service offerings. These converging dynamics—spanning healthcare, biotech, and digital innovation—are collectively driving the rapid global growth of the omics lab services market, positioning it as a cornerstone of next-generation medicine and molecular science.

SCOPE OF STUDY:

The report analyzes the Omics Lab Services market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Omics Lab Hardware Equipment, Omics Lab Testing / Lab Services, Omics Lab Analytics / Interpretation); Services (Proteomics Services, Genomics Services, Transcriptomic Services, Metabolomics Services, Epigenetics Services); Frequency (Continuous Frequency, One-Off Frequency, Repeat Frequency); Business (Diagnostic Labs Business, Hospitals Business, Research Institutes Business); End-Use (Cancer End-Use, Pharmaco End-Use, Reproductive End-Use, Population Studies End-Use, Forensics End-Use, Skincare End-Use, Nutrition, Vitamins & Supplements End-Use, Genealogy End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Agilent Technologies, Inc.
• BD (Becton, Dickinson and Company)
• Beijing Genomics Institute (BGI)
• Biomarker Technologies
• Bruker Corporation
• Danaher Corporation (Beckman Coulter)
• Eurofins Scientific
• Flomics Biotech
• GATC Biotech AG
• Illumina, Inc.
• Macrogen, Inc.
• Novogene Corporation
• PerkinElmer, Inc.
• PhenoSwitch Bioscience
• Q2 Solutions
• QIAGEN N.V.
• Quest Diagnostics
• Shimadzu Corporation
• Sino Biological, Inc.
• Thermo Fisher Scientific Inc.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.